Sanofi (SNYNF) Other Operating Expenses (2009 - 2026)
Sanofi's (SNYNF) quarterly Other Operating Expenses came in at -$1.4 billion in Q1 2026, down 60.15% year-on-year from -$3.5 billion in Q1 2025, and up 72.95% quarter-over-quarter from -$5.1 billion in Q4 2025.
Sanofi (SNYNF) Other Operating Expenses (2009 - 2026) Analysis & Trends
Sanofi has disclosed Other Operating Expenses across 6 years of filings, most recently posting -$1.4 billion for Q1 2026.
- Other Operating Expenses for Q1 2026 came in at -$1.4 billion, down 60.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.3 billion (down 88.23% YoY), and the FY2025 annual result was -$5.1 billion, down 45.81% from the prior year.
- Other Operating Expenses came in at -$1.4 billion for Q1 2026 at Sanofi, up from -$5.1 billion in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of -$656.2 million in Q1 2024 to a low of -$5.1 billion in Q4 2025.
- The 4-year median for Other Operating Expenses is -$2.0 billion (2026), against an average of -$2.4 billion.
- Across the five-year window, Other Operating Expenses tumbled 32.57% in 2024 and tumbled 247.97% in 2025, its largest moves.
- Sanofi's Other Operating Expenses stood at -$2.7 billion in 2023, then sank by 32.57% to -$3.5 billion in 2024, then plunged by 45.81% to -$5.1 billion in 2025, then jumped by 72.95% to -$1.4 billion in 2026.
- The last three Other Operating Expenses figures came in at -$1.4 billion (Q1 2026), -$5.1 billion (Q4 2025), and -$3.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.39 Bn |
| Dec 31, 2025 | -5.15 Bn |
| Sep 30, 2025 | -3.79 Bn |
| Mar 31, 2025 | -869.91 Mn |
| Dec 31, 2024 | -3.53 Bn |
| Sep 30, 2024 | -1.09 Bn |
| Mar 31, 2024 | -656.16 Mn |
| Dec 31, 2023 | -2.66 Bn |
| Dec 31, 2010 | 112.71 Mn |
| Sep 30, 2010 | 50.36 Mn |
| Dec 31, 2009 | 568.54 Mn |
| Sep 30, 2009 | 122.99 Mn |